Search research articles
Contact Us
Filters
Showing results (251-260 of 493) with videos related to
Page
of 50
Sort By:
The Oncologist
|
December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
Luis Meza, David F McDermott, Bernard Escudier, et al.
Molecular Cancer Therapeutics
|
August 12, 2010
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
Rupal S Bhatt, Xiaoen Wang, Liang Zhang, et al.
Clinical Genitourinary Cancer
|
September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
Zeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
Cancer
|
February 2, 2010
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma
Rupal S Bhatt, Jaime Merchan, Robert Parker, et al.
Journal of the National Cancer Institute
|
July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma
J S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1986
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease
M B Atkins, J A Gould, M Allegretta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 9, 2012
Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET
Douglas Van Nostrand, Gauri R Khorjekar, Jeff O'Neil, et al.
The Lancet. Oncology
|
December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Brian I Rini, Sumanta K Pal, Bernard J Escudier, et al.
Cancer
|
February 1, 1994
Tumor activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88 human monoclonal antibody
A K Erdi, B W Wessels, R DeJager, et al.
Kidney International
|
May 31, 2017
Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice
Hongyu Zhang, Viji Nair, Jharna Saha, et al.
Page
of 50
Search research articles
Search
Showing results (251-260 of 493) with videos related to
Sort By:
Page
of 50
The Oncologist
|
December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
Luis Meza, David F McDermott, Bernard Escudier, et al.
Molecular Cancer Therapeutics
|
August 12, 2010
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
Rupal S Bhatt, Xiaoen Wang, Liang Zhang, et al.
Clinical Genitourinary Cancer
|
September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
Zeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
Cancer
|
February 2, 2010
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma
Rupal S Bhatt, Jaime Merchan, Robert Parker, et al.
Journal of the National Cancer Institute
|
July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma
J S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1986
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease
M B Atkins, J A Gould, M Allegretta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 9, 2012
Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET
Douglas Van Nostrand, Gauri R Khorjekar, Jeff O'Neil, et al.
The Lancet. Oncology
|
December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Brian I Rini, Sumanta K Pal, Bernard J Escudier, et al.
Cancer
|
February 1, 1994
Tumor activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88 human monoclonal antibody
A K Erdi, B W Wessels, R DeJager, et al.
Kidney International
|
May 31, 2017
Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice
Hongyu Zhang, Viji Nair, Jharna Saha, et al.
Page
of 50